Leadless Cardiac Pacemakers: Back to the Future.
Despite significant advances in battery longevity, lead performance, and programming features since the first implanted permanent pacemaker was developed, the basic design of cardiac pacemakers has remained relatively unchanged over the past 50 years. Because of inherent limitations in their design, conventional (transvenous) pacemakers are prone to multiple potential short- and long-term complications. Accordingly, there has been intense interest in a system able to provide the symptomatic and potentially lifesaving therapies of cardiac pacemakers while mitigating many of the risks associated with their weakest link-the transvenous lead. Leadless cardiac pacing represents the future of cardiac pacing systems, similar to the transition that occurred from the use of epicardial pacing systems to the familiar transvenous systems of today. This review summarizes the current evidence and potential benefits of leadless pacing systems, which are either commercially available (in Europe) or under clinical investigation.
Helmsley Electrophysiology Center, Icahn School of Medicine, New York, New York.
Marc A
MA
Miller
Homolka Hospital, Prague, Czech Republic.
Petr
P
Neuzil
Helmsley Electrophysiology Center, Icahn School of Medicine, New York, New York.
Srinivas R
SR
Dukkipati
Helmsley Electrophysiology Center, Icahn School of Medicine, New York, New York. Electronic address: vivek.reddy@mountsinai.org.
Vivek Y
VY
Reddy
D001145:Arrhythmias, Cardiac / Q000401:mortality / Q000628:therapy*; D002304:Cardiac Pacing, Artificial / Q000379:methods* / Q000401:mortality; D004567:Electrodes, Implanted / Q000639:trends*; D004867:Equipment Design; D004869:Equipment Safety; D005060:Europe; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial; D015996:Survival Rate; D016896:Treatment Outcome
brachycardia; cardiac resynchronization therapy; electrophysiology